SCHEMBL5650867

SCHEMBL5650867

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccc(C)cc2)c1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.47
ALDH1A1 P00352 8/20 0.47
GAA P10253 5/20 0.45
HPGD P15428 4/20 0.45
NPSR1 Q6W5P4 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KMT2A Q03164 5/20 0.44
MEN1 O00255 4/20 0.44
NPC1 O15118 4/20 0.43
RAB9A P51151 3/20 0.43
HTT P42858 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 5/20 0.41
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CDC7 O00311 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.41
DBF4 Q9UBU7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653998 0.96 MAPT (0.48) MAPTALDH1A1GAAHPGDNPSR1
SCHEMBL5650136 0.95 MAPT (0.51) MAPTALDH1A1GAAHPGDNPSR1
SCHEMBL5652595 0.93 MAPT (0.45) MAPTALDH1A1GAAHPGDKMT2A
SCHEMBL5652764 0.93 MAPT (0.45) MAPTALDH1A1GAAHPGDKMT2A
SCHEMBL5652293 0.92 MAPT (0.44) MAPTALDH1A1GAAHPGDNPSR1
SCHEMBL5654426 0.92 ALDH1A1 (0.50) MAPTALDH1A1GAAHPGDNPSR1
SCHEMBL5647395 0.92 MAPT (0.50) MAPTALDH1A1GAAHPGDKMT2A
SCHEMBL5652339 0.92 MAPT (0.44) MAPTALDH1A1GAAHPGDL3MBTL1
SCHEMBL5648376 0.90 MEN1 (0.47) MAPTALDH1A1GAAHPGDNPSR1
SCHEMBL5654915 0.90 MAPT (0.43) MAPTALDH1A1GAAHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 MAPT 3795/4885ALDH1A1 1498/4885GAA 4108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.